Prospective observational study of monitoring gene alterations in plasma cell-free DNA using droplet digital PCR system during anti-EGFR antibody treatment in patients with RAS wild-type advanced colorectal cancer.

被引：0

作者：

Takahashi, Naoki

Nakamura, Keishi

Kito, Yosuke

Kubota, Eiji

Asayama, Masako

Kumekawa, Yosuke

Hara, Hiroki

Matsushima, Tomohiro

Tsuji, Kunihiro

Kataoka, Hiromi

Tsuyada, Akihiro

Sasaki, Yasushi

Idogawa, Masashi

Tokino, Takashi

Sawada, Takeshi

机构：

[1] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan

[2] Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan

[3] Ishikawa Prefectural Cent Hosp, Kanazawa, Ishikawa, Japan

[4] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan

[5] Saitama Canc Ctr, Saitama, Japan

[6] Ishikawa Prefectural Cent Hosp, Dept Gastroenterol, Kanazawa, Ishikawa, Japan

[7] Riken Genesis Co Ltd, Yokohama, Kanagawa, Japan

[8] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan

[9] Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Sapporo, Hokkaido, Japan

[10] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

172

引用

页码：172 / 172

页数：1

共 13 条

[1] RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer
van Helden, Erik J.
Angus, Lindsay
van Oordt, C. Willemien Menke-van der Houven
Heideman, Danielle A. M.
Boon, Eline
van Es, Suzanne C.
Radema, Sandra A.
van Herpen, Carla M. L.
de Groot, Derk Jan A.
de Vries, Elisabeth G. E.
Jansen, Maurice P. H. M.
Sleijfer, Stefan
Verheul, Henk M. W.
MOLECULAR ONCOLOGY, 2019, 13 (11) : 2361 - 2374
[2] Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Valladares-Ayerbes, Manuel
Garcia-Alfonso, Pilar
Luengo, Jorge Munoz
Caceres, Paola Patricia Pimentel
Trujillo, Oscar Alfredo Castillo
Vidal-Tocino, Rosario
Llanos, Marta
Ayala, Beatriz Llorente
Miron, Maria Luisa Limon
Salud, Antonieta
Nogueras, Luis Cirera
Garcia-Carbonero, Rocio
Safont, Maria Jose
Ferrer, Esther Falco
Aparicio, Jorge
Conesa, Maria Angeles Vicente
Guillen-Ponce, Carmen
Garcia-Teijido, Paula
Magan, Maria Begona Medina
Busquier, Isabel
Salgado, Mercedes
Vila, Ariadna Lloansi
CANCERS, 2022, 14 (24)
[3] Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
Valladares-Ayerbes, Manuel
Safont, Maria Jose
Flores, Encarnacion Gonzalez
Garcia-Alfonso, Pilar
Aranda, Enrique
Munoz, Ana-Maria Lopez
Ferrer, Esther Falco
Nogueras, Luis Cirera
Rodriguez-Salas, Nuria
Aparicio, Jorge
Munoz, Marta Llanos
Caceres, Paola Patricia Pimentel
Trujillo, Oscar Alfredo Castillo
Tocino, Rosario Vidal
Fernandez, Mercedes Salgado
Salud-Salvia, Antonieta
Sureda, Bartomeu Massuti
Garcia-Carbonero, Rocio
Conesa, Maria Angeles Vicente
Vila, Ariadna Lloansi
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10): : 2640 - 2651
[4] Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
Yasui, H.
Okita, Y.
Nakamura, M.
Sagawa, T.
Watanabe, T.
Kataoka, K.
Manaka, D.
Shiraishi, K.
Akazawa, N.
Okuno, T.
Shimura, T.
Shiozawa, M.
Sunakawa, Y.
Ota, H.
Kotaka, M.
Okuyama, H.
Takeuchi, M.
Ichikawa, W.
Fujii, M.
Tsuji, A.
ESMO OPEN, 2023, 8 (05)
[5] Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
Pietrantonio, Filippo
Maggi, Claudia
Di Bartolomeo, Maria
Facciorusso, Maria Grazia
Perrone, Federica
Testi, Adele
Iacovelli, Roberto
Miceli, Rosalba
Bossi, Ilaria
Leone, Giorgia
Milione, Massimo
Pelosi, Giuseppe
de Braud, Filippo
PLOS ONE, 2014, 9 (04):
[6] Phase Ib study of anti-EGFR antibody(SCT200) in combination with anti-PD-1 antibody(SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
Ming Bai
Yao Lu
Chunmei Shi
Jianwei Yang
Wei Li
Xianli Yin
Chenghui Huang
Lin Shen
Liangzhi Xie
Yi Ba
Cancer Biology & Medicine, 2024, 21 (07) : 636 - 650
[7] Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
Bai, Ming
Lu, Yao
Shi, Chunmei
Yang, Jianwei
Li, Wei
Yin, Xianli
Huang, Chenghui
Shen, Lin
Xie, Liangzhi
Ba, Yi
CANCER BIOLOGY & MEDICINE, 2024, 21 (07) : 636 - 650
[8] Quantification and monitoring of treatment response in EGFR mutant non-small cell lung cancer patients using Digital PCR and Therascreen in plasma cell-free tumour DNA.
Ludovini, Vienna
Siggillino, Annamaria
Reda, Maria Sole
Bianconi, Fortunato
Chiari, Rita
Baglivo, Sara
Pistola, Lorenza
Tofanetti, Francesca Romana
Matocci, Roberta
Mencaroni, Clelia
Metro, Giulio
Bennati, Chiara
Minotti, Vincenzo
Crino, Lucio
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer
Zhu, Guanshan
Ye, Xin
Dong, Zhengwei
Lu, Ya Chao
Sun, Yun
Liu, Yi
McCormack, Rose
Gu, Yi
Liu, Xiaoqing
JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03): : 265 - 272
[10] Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase II study
Yang, Lin
Zhang, Wen
Fan, Nanfeng
Cao, Peiguo
Cheng, Ying
Zhu, Lingjun
Luo, Suxia
Zong, Hong
Bai, Yuxian
Zhou, Jianfeng
Deng, Yanhong
Ba, Yi
Liu, Tianshu
Aili, Mayinuer
Yin, Xianli
Gu, Kangsheng
Dai, Guanghai
Ying, Jieer
Shi, Jianhua
Gao, Yajie
Li, Wei
Yu, Guohua
Xie, Liangzhi
Gai, Wenlin
Wang, Yan
Meng, Peng
Shi, Yuankai
EBIOMEDICINE, 2024, 100

← 1 2 →